India's pharma stock crash after Trump's 100% tariff on branded drugs

Core Viewpoint - The announcement of a 100% tariff on imported branded and patented drugs by President Donald Trump has significantly impacted India's pharmaceutical stocks, effective October 1 [1] Group 1: Industry Impact - The tariff is expected to create shockwaves throughout the pharmaceutical industry, particularly affecting companies that rely heavily on exports to the U.S. market [1] - Indian pharmaceutical companies may face increased costs and reduced competitiveness in the U.S. market due to the new tariff [1] Group 2: Market Reaction - Following the announcement, there was a notable decline in the stock prices of major Indian pharmaceutical firms, indicating investor concern over the potential financial implications [1] - The market's immediate reaction reflects the uncertainty surrounding the future of trade relations between India and the U.S. in the pharmaceutical sector [1]